Cellectar Biosciences (CLRB) Price/OCF Ratio: History & Chart

Cellectar Biosciences, Inc.(CLRB)

Biotechnology · Florham Park, NJ

$1.63-0.04 (-2.40%)

Delayed quote: Oct 6, 2026, 11:40 AM EDT

About Cellectar Biosciences, Inc.

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.

Florham Park, NJ

11 employees

www.cellectar.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James V. Caruso

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Cellectar Biosciences, Inc. (CLRB)	$13.02M	N/A	N/A	N/A	N/A
Lantern Pharma Inc. (LTRN)vs ›	$13.27M	N/A	N/A	N/A	N/A
Passage Bio, Inc. (PASG)vs ›	$13.27M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$13.01M	N/A	N/A	N/A	N/A
Dare Bioscience, Inc. (DARE)vs ›	$12.57M	N/A	3.83	3.83	3.83
Optimi Health Corp. (OPTH)vs ›	$13.44M	N/A	N/A	N/A	N/A
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$11.95M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.81M	N/A	N/A	N/A	N/A
IRIDEX Corporation (IRIX)vs ›	$12.12M	N/A	9.81	9.81	9.81
Vyome Holdings, Inc. (HIND)vs ›	$13.97M	26.63	28.16	28.16	28.16

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Cellectar Biosciences, Inc. (CLRB)

$13.02M

N/A

Lantern Pharma Inc. (LTRN)vs ›

$13.27M

N/A

Passage Bio, Inc. (PASG)vs ›

$13.27M

N/A

Cytosorbents Corporation (CTSO)vs ›

$13.01M

N/A

Dare Bioscience, Inc. (DARE)vs ›

$12.57M

N/A

3.83

Optimi Health Corp. (OPTH)vs ›

$13.44M

N/A

Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›

$11.95M

N/A

IN8bio, Inc. (INAB)vs ›

$13.81M

N/A

IRIDEX Corporation (IRIX)vs ›

$12.12M

N/A

9.81

Vyome Holdings, Inc. (HIND)vs ›

$13.97M

26.63

28.16

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

CLRB Price/OCF Ratio Metrics

CLRB Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics